Tropicamide
Based on 5 publication(s) in Google Scholar
Tropicamide (Ro 1-7683) is a selective M4 muscarinic acetylcholine receptor antagonist. When used as an eye drop, Tropicamide causes short-term mydriasis (pupil dilation) and cycloplegia. Tropicamide can be used in the research of neurological diseases, such as epilepsy.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.87%
- CAS No.: 1508-75-4
- Formule: C17H20N2O2
- Masse moléculaire:284.35
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-B1205
Atropine
-
HY-101381
Otenzepad
-
HY-17037A
Pirenzepine
-
HY-B0471
Phenylephrine hydrochloride
-
HY-100958
4-DAMP
-
HY-W020468
Linopirdine
-
HY-B0321R
Tropicamide (Standard)
-
HY-B1388
Homatropine (methylbromide)
-
HY-17360
Tiotropium Bromide
-
HY-17037
Pirenzepine dihydrochloride
-
HY-B0118A
Vecuronium bromide
-
HY-17368
Rivastigmine
Publications Citing Use of MedChemExpress (MCE) Tropicamide
More
Activité biologique
|
mAChR4 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fmr1 knock-out (Fmr1KO) mouse model[3]
-
Dosage:2, 5, 20, 40 mg/kg
-
Administration:Intraperitoneal injection (i.p.), single dose
-
Result:Decreased marble burying behavior in Fmr1KO mice, increased activity, improved learning and memory, and significantly reduced audiogenic seizures.
-
Animal Model:Pilocarpine (HY-B0726A)-induced tremulous jaw movement model (Rat)[4]
-
Dosage:1.25, 2.5, 5.0, 10.0, 20.0 mg/kg
-
Administration:Intraperitoneal injection (i.p.), single dose
-
Result:Significantly reduced pilocarpine-induced tremulous jaw movements.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1508-75-4
-
Appearance Solid
-
Masse moléculaire 284.35
-
Formule C17H20N2O2
-
Color White to off-white
-
SMILES
O=C(N(CC)CC1=CC=NC=C1)C(C2=CC=CC=C2)CO
-
Synonyms
Ro 1-7683
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Histamine H1 receptors in dentate gyrus-projecting cholinergic neurons of the medial septum suppress contextual fear retrieval in mice. [Abstract]2024 Jul 10;15(1):5805. PMID: 38987240 -
Cell Rep Med
Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. [Abstract]2024 Feb 20;5(2):101388. PMID: 38262412 -
FASEB J
Long non-coding RNA SNHG11 regulates the Wnt/β-catenin signaling pathway through rho/ROCK in trabecular meshwork cells. [Abstract]2023 Apr;37(4):e22873. PMID: 36929360 -
Toxicol Appl Pharmacol
In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1. [Abstract]2024 May:486:116945. PMID: 38688424 -
Indian J Ophthalmol
Ranitidine protects Müller cells against ferroptosis in diabetic retinopathy by regulating the AKT1/GSK3β pathway. [Abstract]2026 Feb 1;74(2):250-258. PMID: 41581041
Solvant et solubilité
DMSO : 25 mg/mL (87.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lazareno, S., N.J. Buckley, and F.F. Roberts, Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol Pharmacol, 1990. 38(6): p. 805-15. [Content Brief]
[2]. Hernandez, M., et al., Different muscarinic receptor subtypes mediating the phasic activity and basal tone of pig isolated intravesical ureter. Br J Pharmacol, 1993. 110(4): p. 1413-20. [Content Brief]
[3]. Veeraragavan S, et al. The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide. Behav Neurosci. 2011 Oct;125(5):783-90. [Content Brief]
[4]. Betz AJ, et al. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5168 mL | 17.5840 mL | 35.1679 mL | 87.9198 mL |
| 5 mM | 0.7034 mL | 3.5168 mL | 7.0336 mL | 17.5840 mL | |
| 10 mM | 0.3517 mL | 1.7584 mL | 3.5168 mL | 8.7920 mL | |
| 15 mM | 0.2345 mL | 1.1723 mL | 2.3445 mL | 5.8613 mL | |
| 20 mM | 0.1758 mL | 0.8792 mL | 1.7584 mL | 4.3960 mL | |
| 25 mM | 0.1407 mL | 0.7034 mL | 1.4067 mL | 3.5168 mL | |
| 30 mM | 0.1172 mL | 0.5861 mL | 1.1723 mL | 2.9307 mL | |
| 40 mM | 0.0879 mL | 0.4396 mL | 0.8792 mL | 2.1980 mL | |
| 50 mM | 0.0703 mL | 0.3517 mL | 0.7034 mL | 1.7584 mL | |
| 60 mM | 0.0586 mL | 0.2931 mL | 0.5861 mL | 1.4653 mL | |
| 80 mM | 0.0440 mL | 0.2198 mL | 0.4396 mL | 1.0990 mL |
Tropicamide Related Classifications
HY-B0321 Related Classifications
Powered by Bioz